OncoSil Medical (ASX:OSL) has announced the appointment of Professor Ricky Sharma to its board as a non-executive director.
Professor Sharma, whose appointment takes effect from 1 November, is an international authority on the translation of radiobiology from the laboratory to the clinic and on the multi-modality treatment of cancer with precision radiotherapy.
He is currently vice president of clinical affairs at Varian. Professor Sharma is also an honorary consultant in clinical oncology at University College London Hospitals, where he has a clinical practice in radiotherapy and chemotherapy. He has led a research team at University College London that translated discoveries in radiotherapy research to clinical trials to improve treatment for patients with cancer.
Professor Sharma was previously an associate professor at the University of Oxford and an honorary consultant in clinical oncology at Oxford University Hospitals. He has over 200 publications in peer-reviewed scientific journals, including Lancet and Nature journals.
Professor Sharma has previously been the chair of radiation oncology at University College London and a scientific group leader at the UCL Cancer Institute and he was a former chair of working groups for NHS/NICE evaluations of novel radiotherapy treatments. He graduated in medicine from the University of Cambridge.
Professor Ricky Sharma said, “I believe that OncoSil has the ability to rapidly transform the way pancreatic cancer is treated for future patients. I am looking forward to providing the OncoSil team with my perspective and insights on commercialisation and clinical advancement.”
OncoSil chair Dr Chris Roberts said, “We are privileged to have such an experienced clinician joining the team. Ricky’s experience in radiotherapies and oncology will enhance our expertise as we bring the OncoSil device to market, and further develop market opportunities for the company.”